September 24 - 27, 2017
Disney’s Boardwalk Inn
Orlando, Florida, USA
Abstract submission deadline: Tuesday, July 11
Advance registration deadline: Monday, August 14
View Program PDF (as of 9/22/17)
Sunday, September 24
Monday, September 25
Tuesday, September 26
Wednesday, September 27
Sunday, September 24
Opening Keynote Session Session Chairs: Cory Abate-Shen, Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center, New York, New York, and Kevin M. Haigis, Beth Israel Deaconess Medical Center, Boston, Massachusetts6:00 p.m.-8:00 p.m.
Welcome RemarksCory Abate-Shen
Engineering the cancer genomeTyler Jacks, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts
Unearthing mechanisms of malignant progression and resistance of cancer stem cellsElaine Fuchs, The Rockefeller University, New York, New York
Opening Reception8:00 p.m.-10:00 p.m.
Monday, September 25
Continental Breakfast / Roundtable Discussions7:30 a.m.-8:30 a.m.
Plenary Session 1: Technological Advances for Modeling Cancer in Mice Session Chair: Julien Sage, Stanford University School of Medicine, Stanford, California8:30 a.m.-10:30 a.m.
Cancer modeling in the CRISPR ageAndrea Ventura, Memorial Sloan Kettering Cancer Center, New York, New York
Modeling colorectal cancer in vivo through CRISPR-based genome editing*Lukas E. Dow, Weill Cornell Medical College, New York, New York
Quantitative and multiplex analysis of the genomic determinants of tumorigenesisMonte Winslow, Stanford University School of Medicine, Stanford, California
Capturing the integration of Ras-mutant cells into normal epithelial tissue using live imaging*Cristiana M. Pineda, Yale University, New Haven, Connecticut
Genetic dissection of cancer development, therapy response, and resistance in mouse models of breast cancerJos Jonkers, Netherlands Cancer Institute, Amsterdam, The Netherlands
Break10:30 a.m.-11:00 a.m.
Plenary Session 2: Elucidating Cancer Mechanisms Using Mouse Models Session Chair: Karen M. Cichowski, Brigham & Women's Hospital, Boston, Massachusetts11:00 a.m.-1:00 p.m.
Driver mutations and cell-of-origin as critical factors determining the phenotypic characteristics of thoracic tumor subtypesAnton J.M. Berns, Netherlands Cancer Institute, Amsterdam, The Netherlands
The tumor suppressor BAP1 regulates the Hippo pathway in pancreatic ductal adenocarcinoma*Anwesha Dey, Genentech Inc., South San Francisco, California
Deconstructing p53 pathways in tumor suppressionLaura D. Attardi, Stanford University School of Medicine, Stanford, California
p120 catenin loss drives pancreatic cancer EMT and metastasis through activation of calcium signaling*Jason R. Pitarresi, University of Pennsylvania, Philadelphia, Pennsylvania
Somatic p53 mutations drive development of triple negative breast cancer with evolutionarily distinct metastasesGuillermina Lozano, The University of Texas MD Anderson Cancer Center, Houston, Texas
Poster Session A Highlights1:00 p.m.-1:15 p.m.
Somatic engineering of the mammary gland for the development of novel mouse models of triple negative breast cancerStefano Annunziato, Netherlands Cancer Institute, Amsterdam, The Netherlands
Potent synergism between FBXW7 and PI3K signalling in a mouse model of endometrial carcinogenesisIleana C. Cuevas, UT Southwestern Medical Center, Dallas, Texas
Cross-species oncogenomics approach identifies PTPN11 as an oncogene and potential therapeutic target in melanomaMinjung Kim, Moffitt Cancer Center, Tampa, Florida
Investigating mechanisms of obesity-mediated pancreatic cancer progressionMandar Deepak Muzumdar, Koch Institute at MIT, Cambridge, MassachusettsPoster Session A / Lunch1:15 p.m.-3:30 p.m.
Plenary Session 3: Modeling the Tumor Microenvironment Session Chair: Kwok-Kin Wong, New York University Langone Medical Center, New York, New York4:00 p.m.-6:00 p.m.
Metabolic recycling in cancerMarcia Haigis, Harvard Medical School, Boston, Massachusetts
Lineage specifiers SOX2 and NKX2-1 inversely regulate lung tumor immune microenvironment*Trudy G. Oliver, University of Utah, Salt Lake City, Utah
Evaluation of the microenvironment in anti-tumor immune responsesMarcus W. Bosenberg, Yale University School of Medicine, New Haven, Connecticut
Contribution of mutant microenvironment to hereditary cancer: Single-cell gene expression profiling of a genetically engineered mouse model of human hereditary BRCA1-related breast cancer*Carman M. Li, Harvard Medical School, Boston, Massachusetts
Tumor microenvironment: Stroma-tumor cell signaling defined by a cross-species approachGustavo W. Leone, Medical University of South Carolina Hollings Cancer Center, Charleston, South Carolina
Top of page
Tuesday, September 26
Plenary Session 4: Stem Cells and Developmental Pathways in Cancer Session Chair: Michael M. Shen, Columbia University College of Physicians & Surgeons, New York, New York8:30 a.m.-10:30 a.m.
Intra- and inter-tumoral heterogeneity and response to therapy in mouse models of SCLCJulien Sage, Stanford University School of Medicine, Stanford, California
Elucidating mechanisms of p53-deficient breast cancer development via lineage tracing and clonal analysis*Zhe Li, Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts
Imaging stem cell signals in cancer heterogeneity and therapy resistanceTannishtha Reya, University of California San Diego, La Jolla, California
Altered nucleolar trafficking of the Blm helicase in the mouse reduces size, increases DNA damage and tumor susceptibility, and facilitates premature aging* Joanna L. Groden, The Ohio State University College of Medicine, Columbus, Ohio
Lessons from modeling neural tumors in miceLuis F. Parada, Memorial Sloan Kettering Cancer Center, New York, New York
Break10:30 a.m.-11:00 a.m.Plenary Session 5: Genetics, Genomics, and Systems Biology Session Chair: Monte M. Winslow, Stanford University School of Medicine, Stanford, California11:00 a.m.-1:00 p.m.
Normal and cancer stem cells in multistage carcinogenesisAllan Balmain, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California
The global proteome and phospho-proteome of K-Ras mutant tissuesKevin M. Haigis, Beth Israel Deaconess Medical Center, Boston, Massachusetts
RNA sequencing–based analysis of transposon-induced tumors reveals novel insights into disease pathogenesis*David A. Largaespada, University of Minnesota, Minneapolis, Minnesota
Of mice and men: Using systems biology approaches to study human cancerCory Abate-Shen, Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center, New York, New York
Lunch (on Own)1:00 p.m.-2:30 p.m.
Plenary Session 6: Beyond Genetically Engineered Mouse Models Session Chair: Guillermina Lozano, The University of Texas MD Anderson Cancer Center, Houston, Texas2:30 p.m.-4:15 p.m.
GEMMs and GEOs to characterize pancreatic cancer initiation and progressionDavid A. Tuveson, Cold Spring Harbor Laboratory Cancer Center, Cold Spring Harbor, New York
Organoid models of bladder cancerMichael M. Shen, Columbia University College of Physicians & Surgeons, New York, New York
Investigating lung cancer cells-of-origin using three dimensional organoid cultures*Christine Fillmore Brainson, University of Kentucky, Lexington, Kentucky
The tumor immune landscape and heterogeneity projectsPier Paolo Pandolfi, Beth Israel Deaconess Medical Center, Boston, Massachusetts
Break4:15 p.m.-4:45 p.m.
Keynote Address Session Chair: Katerina A. Politi, Yale Cancer Center, New Haven, Connecticut4:45 p.m.–5:40 p.m.
Interrogating cancer drivers and dependencies using non-germline mouse modelsScott W. Lowe, Memorial Sloan Kettering Cancer Center, New York, New York
Poster Session B Highlights5:40 p.m.-5:55 p.m.
A genetically engineered mouse model of de novo bone metastasisJuan Martin Arriaga, Columbia University Medical Center, New York, New York
Neutrophils and Snail orchestrate the establishment of a pro-tumor microenvironment in lung adenocarcinomaEtienne Meylan, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
Acinar cell expansion: A new step in pancreatic tumorigenesisPatrick Neuhoefer, Stanford University, Stanford, California
Activating K-RasA146T mutations induce Mapk-dependent hyperproliferation in the intestinal epitheliumEmily Poulin, Beth Israel Deaconess Medical Center, Boston, Massachusetts
BRAF inhibition and cytokine therapy for melanoma: a novel rational combined approachGabriele Romano, The University of Texas MD Anderson Cancer Center, Houston, Texas
A SOX9+ bile duct progenitor as a cell of origin of hepatocellular carcinoma Patrick Viatour, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Poster Session B / Reception6:00 p.m.-8:30 p.m.
Wednesday, September 27
Continental Breakfast7:30 a.m.-8:15 a.m.
Plenary Session 7: Targeting the Tumor Microenvironment Session Chair: Martin McMahon, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah8:15 a.m.-10:00 a.m.
Lung cancer mouse models for preclinical testing of novel and immune therapiesKwok-Kin Wong, New York University Langone Medical Center, New York, New York
The immune microenvironment in lung cancer: Lessons from mouse modelsKaterina A. Politi, Yale Cancer Center, New Haven, Connecticut
Targeting the drug- and immune-privileged sanctuary of pancreas cancerSunil R. Hingorani, Fred Hutchinson Cancer Research Center, Seattle, Washington
Selective lethality of cisplatin in pancreatic cancer is dependent on mitotic functions of BRCA2*Kenneth P. Olive, Columbia University Medical Center, New York, New York
Break10:00 a.m.-10:15 a.m.
Plenary Session 8: Using Mouse Models to Study Drug Resistance Session Chair: Marcus W. Bosenberg, Yale University School of Medicine, New Haven, Connecticut10:15 a.m.-12:00 p.m.
Using mouse models to improve cancer therapyMichael T. Hemann, David H. Koch Institute for Integrative Cancer Research at MIT, Boston, Massachusetts
Clonal dynamics during breast cancer dormancy and recurrence*James V. Alvarez, Duke University, Durham, North Carolina
Mutational activation of PI3-kinase-α promotes de-differentiation of BRAFV600E-driven lung tumor cellsMartin McMahon, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah
Using mouse models to develop therapies for Ras-driven cancersKaren M. Cichowski, Brigham & Women's Hospital, Boston, Massachusetts
Closing Remarks12:00 p.m.-12:45 p.m.
Julien Sage, Stanford University School of Medicine, Stanford, California
*Short talk from proffered abstract